NASDAQ: TSVT2seventy Bio Inc Stock
$4.98+0.01 (+0.2%)
Updated Apr 17, 2025
TSVT Price
$4.98
Fair Value Price
N/A
Market Cap
$260.65M
52 Week Low
$2.29
52 Week High
$5.30
P/E
-4.53x
P/B
1.24x
P/S
4.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$37.86M
Earnings
-$57.25M
Gross Margin
52.4%
Operating Margin
-151.2%
Profit Margin
-151.2%
Debt to Equity
1.28
Operating Cash Flow
-$85M
Beta
1.32
Next Earnings
May 1, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TSVT Overview
2seventy bio Incorporated develops gene-therapy-based cancer treatments in the U.S. Its pipeline includes a treatment formultiple myeloma. 2seventy bio, Inc. collaboratest with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TSVT's potential to beat the market
- TSVT doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TSVT
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important TSVT news, forecast changes, insider trades & much more!
TSVT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TSVT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TSVT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TSVT is good value based on its book value relative to its share price (1.24x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
TSVT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TSVT due diligence checks available for Premium users.
Valuation
TSVT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.53x
Industry
-177.72x
Market
27.98x
TSVT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.24x
Industry
4.05x
TSVT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TSVT's financial health
Profit margin
Revenue
$2.9M
Net Income
-$19.5M
Profit Margin
-667.1%
TSVT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TSVT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$479.5M
Liabilities
$268.7M
Debt to equity
1.28
TSVT's short-term assets ($187.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TSVT's long-term liabilities ($228.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TSVT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TSVT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.5M
Investing
$22.0M
Financing
$3.0k
TSVT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TSVT vs Biotech Stocks
2seventy Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.